



129th MAINE LEGISLATURE

LD 793

LR 1130(02)

An Act To Improve Accountability of Opioid Manufacturers

Fiscal Note for Bill as Amended by Committee Amendment " "

Committee: Judiciary

Fiscal Note Required: Yes

Fiscal Note

Current biennium revenue increase - Other Special Revenue Funds

	FY 2019-20	FY 2020-21	Projections FY 2021-22	Projections FY 2022-23
Appropriations/Allocations				
Other Special Revenue Funds	\$53,500	\$53,500	\$53,500	\$3,500

Fiscal Detail and Notes

This bill includes Other Special Revenue Funds allocations of \$53,000 in fiscal year 2019-20 and \$53,000 in fiscal year 2020-21 to the Licensing and Enforcement program within the Department of Professional and Financial Regulation for the contracting and general operating costs associated with the development of the registration fee review report, determination and report of exempted medications, rulemaking and additional board meetings.

This bill raises the annual license fee for a manufacturer of opioid medication to \$55,000 and establishes an annual registration fee of \$250,000 for a manufacturer of an opioid product that sells, delivers or distributes an opioid medication in the State and requires that the revenue from these fees, excluding \$325 per license that may be retained by the Department of Professional and Financial Regulation, be credited to the Opioid Use Disorder Prevention and Treatment Fund. The estimated revenue to be received from the license and registration fees can not be estimated at this time.

The bill also includes Other Special Revenue Funds allocations to the Department of Health and Human Services of \$500 beginning in fiscal year 2019-20 for the base allocation for the Opioid Use Disorder Prevention and Treatment Fund.